Obesity is a major public health concern affecting an increasing proportion of reproductive-aged women. Avoiding unintended pregnancy is of major importance, given the increased risks associated with pregnancy, but obesity may affect the efficacy of hormonal contraceptives by altering how these drugs are absorbed, distributed, metabolized or eliminated. Limited data suggest that long-acting, reversible contraceptives maintain excellent efficacy in obese women. Some studies demonstrating altered pharmacokinetic parameters and increased failure rates with combined oral contraceptives, the contraceptive patch and emergency contraceptive pills suggest decreased efficacy of these methods. It is unclear whether bariatric surgery affects hormonal contraceptive efficacy. Obese women should be offered the full range of contraceptive options, with counseling that balances the risks and benefits of each method, including the risk of unintended pregnancy.
future science group www.futuremedicine.com CME Obesity and being overweight represent one of the largest preventable health conditions, affect ing 1.4 billion adults globally, including nearly 300 million obese women [101] . Obesity is associ ated with adverse health effects, such as hyperten sion, hyperlipidemia and Type II diabetes. For women of reproductive age, obesity confers addi tional risks during pregnancy, such as increased rates of spontaneous abortion, preeclampsia, ges tational diabetes, shoulder dystocia and cesarean section [1] . Thus, preventing unintended preg nancy is at least as important for obese women, as for women contending with any chronic health condition.
There are many ways to quantify obesity, the most common being the BMI (BMI = weight in kilograms divided by the square of height in meters). BMI provides a continuous mea surement of weightforheight, with cutoffs for overweight and different classes of obesity as presented in Table 1 [2] . Class 1 obesity is consid ered to be moderate, class 2 severe and class 3 is considered as morbid obesity.
Obese individuals experience a number of physiologic changes compared with normal weight individuals, ranging from an increase in cardiac output to alterations in liver enzyme function [3] . Some of these alterations have the potential to affect how drugs are absorbed, dis tributed, metabolized and eliminated. Changes in any of these processes may affect the efficacy of a drug. There is concern that the efficacy of hormonal contraception in obese women may be adversely affected for these reasons.
In order to understand the potential impact that obesity may have on contraceptive efficacy, we review some basic concepts of pharmacokinet ics (PK), and briefly discuss how obesity might affect PK parameters. We then review available evidence for the efficacy of specific contraceptive methods in obese women. While efficacy is a separate concern from safety, concerns for adverse effects may limit providers' willingness to provide certain contraceptives to obese women. There fore, a brief discussion of contraceptive safety in obese women is included in this review. Finally, we discuss the use of contraceptives in women who have had bariatric surgery, an increasingly common treatment for obesity among women of r eproductive age.
PK implications: cause for concern?
PK refers to the study of how drugs move through the body, encompassing how a drug is absorbed, distributed, metabolized and eliminated [4] . Important PK parameters, which are used to quantify these attributes are calculated from the drug's concentrations in blood. Such parameters include bioavailability, volume of distribution (Vd), clearance, halflife (t½), area under concen tration timecurve (AUC) and the minimum and maximum serum concentrations (C min and C max , respectively). A drug's efficacy is very often a func tion of one or more of its PK parameters [5] . The PK parameters that are most relevant for efficacy of contraceptive steroids are uncertain. Obesity itself causes a number of physiologic and metabolic changes that may affect PK parameters of systemi cally administered drugs. Whether or not this CME subsequently affects contraceptive efficacy is not certain, but an effect is believed to be plausible [6] .
Absorption
Drug absorption depends on multiple factors, including a drug's dose and route of admin istration. Absorption influences a drug's bio availability, or the amount absorbed into the sys temic circulation. Drugs that are administered intravenously have 100% bioavailability, since they are immediately delivered into the circula tion. The bioavailability of orally dosed drugs, on the other hand, depends on how efficiently the compound is absorbed through the gut, as well as how much is metabolized by the gastro intestinal epithelium or the liver. For instance, an intravenous dose of ethinyl estradiol (EE) has a bioavailability of 100%, while the same dose given orally has a bioavailability of only 44% [7] . Oral drugs enter the portal (hepatic) circulation after they are absorbed by the gut. The hepatic metabolism that occurs before the drug reaches the systemic circulation is referred to as firstpass metabolism; this can greatly affect the proportion of the drug that is avail able to exert its therapeutic effect. Alternate dos ing routes, such as transdermal, transvaginal or intramuscular, avoid firstpass metabolism and can improve the drug's bioavailability compared with oral dosing. Obese individuals may have increased absorp tion through the gut due to increased gut perfu sion (a result of increased cardiac output) and increased gastric emptying time [7] . A drug that is delivered transdermally or intramuscularly may exhibit slower absorption in the presence of increased fat deposits. Both of these changes can affect bioavailability. Little is known about whether obesity affects the absorption of p arenteral drugs.
Distribution
After absorption, a drug is dispersed throughout the body into various compartments depending on its chemical properties, such as size, charge, lipophilicity or affinity for plasma proteins. These factors influence the drug's Vd, the appar ent space in the body that the drug can occupy. The total exposure to a drug is measured by the AUC, which is calculated from serial serum con centrations drawn at multiple time points. Those concentrations can also be used to determine C min and C max after a single dose of the drug. Obesity may alter Vd through changes in plasma proteins that can either increase or decrease the amount of drug that is proteinbound. Since the unbound fraction of drug exerts the therapeutic effect, changes in protein binding can alter the drug's activity [5] .
Metabolism
The effects of obesity on drug metabolism are unclear. Obesity is associated with fatty infiltra tion of the liver, which can lead to global liver dys function and reduced enzyme activity, especially in the morbidly obese [3] . It is also associated with decreased activity of the hepatic enzyme CYP3A4, the enzyme primarily responsible for metabolism of contraceptive steroids [7] . Adipose tissue may also have some intrinsic metabolic activity, which could affect hormonal contraceptives.
Elimination
Clearance refers to how quickly the body can eliminate the drug, usually via the kidneys or liver. A drug's t½ refers to the time required for the drug's concentration to be reduced by half, and this parameter is a function of both Vd and clearance. The t½ influences the time needed for the drug to reach steadystate concentration, which typically requires four to five halflives [8] .
The rate of drug elimination may be increased due to obesityrelated increases in renal clearance [7] . However, the increased clearance may not lead to changes in the drug's t½ if it is offset by an increase in Vd [3] . Drugs that are lipophilic may have decreased clearance in obese women, if the drug experiences slower release from fat than other tissues [7] .
Pharmacodynamics
The effects a drug has on a body's functions, known as pharmacodynamics, are the main reason to be concerned about PK alterations. Examples of contraceptive pharmacodynamic outcomes are suppression of ovarian follicu lar development, alterations in characteristics of cervical mucus or hormonal effects on the endometrium. It is generally accepted that PK influence pharmacodynamic findings, although the exact relationships between PK and phar macodynamics may not be entirely clear. This seems to be especially true for contraceptive hormones, for which there can be large intra individual and interindividual variability in PK parameters, particularly for the hormones in oral contra ceptives [9] . This variability may account for differing responses to a given contraceptive, such as bleeding patterns or contraceptive fail ure. Ultimately, the PK and pharmacodynamic ramifications of obesity and contraception remain poorly understood.
Much of the concern for altered hormonal con traceptive efficacy in obese women stems from worries about how weightrelated physiologic alterations affect the PK of estrogenic and pro gestogenic contraceptive hormones, and whether this translates into altered pharmacodynamics. Below, available data about efficacy of common hormonal contraceptives when used by obese or overweight women are discussed.
Used correctly, modern contraceptives are very effective at preventing unintended preg nancy. Comparisons of perfect use and typical use estimates are presented in Table 2 [10] . Perfect use can be equated with efficacy -how well a given contraceptive can work, if used exactly as intended. Depending on user burden, typical use failure rates (contraceptive effectiveness) may diverge significantly from perfectuse failure rates. Typicaluse failure rates are gen erally affected by factors such as contraceptive compliance or adherence, whereas perfectuse failure rates (efficacy) reflect inherent proper ties of a method. No published studies clearly demonstrate that obese women are less likely than nonobese women to be compliant with a contraceptive method. Whether obesity has an impact on contraceptive efficacy is the concern that this article attempts to address.
Progestin-only contraceptives
Progestinonly contraceptives include long acting reversible contraceptives (intrauterine devices [IUDs] and implants), injectables and progestinonly pills. The two available levo norgestrel (LNG)releasing intrauterine systems (LNGIUS) contain the progestin levonorgestrel and are highly effective at preventing pregnancy, one for 3 years, and one for at least 5 years [7] . The LNGIUS delivers hormone directly to the endometrium where it leads to endometrial thinning and decidualization; ovulation may be suppressed in approximately half of cycles [11] . Progestinonly contraceptive implants deliver a continuous dose of progestin and prevent preg nancy for up to 3 years. Injectable progestins provide several weeks to months of contracep tive effect. Injectables and implants prevent pregnancy via ovulation suppression and pro gestinmediated effects on the cervical mucus and endometrium.
Intrauterine devices
Owing to the contraceptive effect of IUDs occuring primarily via local actions on the uterus, there is no reason to think that IUDs would be less effective in obese women than in women of normal weight. There are few studies that evaluate differences in IUD contraceptive efficacy by weight. There are now two types of LNGcontaining IUDs available in the USA. The more widely available device delivers 20 µg LNG/day for at least 5 years, and is likely to be effective for even longer. A newlyapproved, slightly smaller IUD is intended to provide contraception for 3 years, with a lower release rate of LNG (14 µg/day). No data reporting dif ferential efficacy by weight are available. The manufacturer reports that women with a BMI up to 55 kg/m 2 were enrolled in the clinical trial leading to US FDA approval, although the mean BMI was 25.3 kg/m 2 [12] . BMI was not reported for women who experienced the five pregnancies that occurred among 1432 participants in the first year of use.
An analysis of data from the Contraceptive CHOICE Project (a large, prospective study in St. Louis, MO, USA) that provided more than 9000 women with free contraception estimated the failure rate of the IUD (both the LNGIUS and copper IUD) in obese and normalweight women [13] . Over 4200 women received an IUD, the majority of whom selected the LNGIUS [102] . A total of 12 pregnancies were observed among IUD users (five in normal weight, none in overweight and seven in obese women) over the course of 5985 womanyears of use. Failure rates for the IUD were less than one per 100 womanyears, and did not differ by BMI cat egory. There are anecdotal reports of IUD inser tion being more technically difficult in obese women, with theoretical concern for greater likelihood of expulsion, but published reports that address this issue are difficult to find. Progestin-only pill 0.3 9
Rates refer to the percentage of women using the method who experience an unintended pregnancy during the first year of method use. These apply to the general population; specific estimates are not available for overweight/obese women. Failure rates refer to expected number of pregnancies per 100 woman-years of use. Adapted with permission from [10] . 
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Owing to its high efficacy, which is preserved across the BMI spectrum, intrauterine contra ception is an excellent choice for obese women wishing to delay or avoid pregnancy.
Contraceptive implants Etonogestrel implant
Prescribing information for the etonogestrel (ENG) implant indicates that serum ENG levels decline with increasing body weight [14] . Only one study directly measured the PK of the ENG contraceptive implant in obese women [15] . In comparing ENG concentra tions in 13 obese women (BMI ≥30 kg/m 2 ) to four normalweight women and historical controls, the authors found an almost 50% lower ENG AUC in the obese women com pared with normalweight women. They also estimated that obese women would experience 40% lower ENG exposure over the life of the implant. While none of the obese women were projected to have an ENG level below that which is believed to reliably suppress ovula tion (90 pg/ml) [16] , this study raised concerns that the implant may not be effective for the full 3 years in obese women.
Women who weighed greater than 130% of ideal body weight were generally excluded from efficacy studies of the ENG implant. A postmarketing study of 923 women using the ENG implant included 134 women who weighed more than 70 kg. These women con tributed 218 womanyears of contraceptive use (only 4 womanyears of use for women >90 kg), and the authors reported that method fail ure rates were low and not affected by body weight [17] . Researchers at the Contraceptive CHOICE Project also estimated the failure rate of the ENG implant in obese and nor malweight women [13] . There was one preg nancy observed in an obese participant during 1377 womenyears of implant use, for a cumu lative failure rate among obese women of 0.23 per 100 womanyears. There was no significant difference in failure rates between the implant groups for any BMI category.
Finally, a 2011 case series reported the experiences of three morbidly obese women who had an ENG implant placed 1-2 months prior to undergoing RouxenY gastric bypass surgery [18] . Serum ENG concentrations were measured prior to surgery, and 3 and 6 months after surgery. Two out of three women had lower preoperative ENG concentrations than normalweight historical controls, and all three women's ENG serum concentrations decreased at 3 and 6 months postoperatively. While all three had levels sufficient to prevent ovulation, the authors also raised concerns that the lower concentrations may indicate a need to replace the implant sooner than the licensed 3 years.
Levonorgestrel implants
While not currently available in the USA, sev eral tworod LNG implants are commonly used worldwide. Data on efficacy in obese women are sparse. One study comparing the tworod LNG implant with the sixrod LNG implant (no lon ger used) enrolled 598 women, approximately 11% of whom had a body weight greater than 70 kg. Of the three recorded pregnancies in the LNG tworod group, all were in women who weighed less than 70 kg. The authors concluded that body weight does not reduce the efficacy of the LNG implant [19] .
In summary, the limited available published data on efficacy of progestinonly implants in obese women is reassuring. These highly effec tive, longacting contraceptives may also be an excellent option.
Injectable contraception Depot medroxyprogesterone acetate
Depot medroxyprogesterone acetate (DMPA) is an injectable contraceptive that is widely used around the world. It is provided as an intra muscular (im.) injection of 150 mg DMPA and provides highly effective, reversible contracep tion for approximately 3 months [20] . The effi cacy of the intramuscular formulation is not known to be decreased in obese women. The subcutaneous (sc.) formulation (DMPAsc.) delivers a lower dose of DMPA (104 mg) and provides comparable contraceptive effect.
A randomized, prospective, evaluatorblinded trial compared the effects of DMPAim. to DMPAsc. [21] . Women were followed through 3 months of a treatment cycle and until they resumed ovulation or up to 1 year after stopping the study drug. Results were stratified by BMI category, and no differences in PK parameters were found among different BMI categories. The mean trough concentration of medroxyproges terone acetate was lowest in women with a BMI >30 kg/m 2 , but was still above the threshold needed to suppress ovulation (200 pg/ml).
Another study evaluated the PK and pharmaco dynamics of DMPAsc. in women falling into three BMI categories: class 3 obese (BMI ≥40 kg/m 2 ), class 1-2 obese (BMI 30-39.9 kg/m 2 ) and nor mal weight (BMI 18.5-24.9 kg/m 2 ) [22] . Serum medroxyprogesterone acetate concentrations were consistently lower in obese subjects than normalweight subjects, but remained above the threshold needed for ovulation suppression. One participant with class 3 obesity became preg nant during the study, and it is believed that she conceived during the first week after DMPAsc. administration, during which she did not use a backup method as recommended. These studies suggest that obesity does not reduce the efficacy of DMPA. For use of the im. formulation, the depth of subcutaneous fat in some obese women may necessitate use of longer needles than those usually used for im. injections [23] .
Norethisterone enanthate
Norethisterone enanthate is another injectable progesteroneonly contraceptive method that is given every 8 weeks. It is not available in the USA, but is used in some other countries.
A study comparing the PK of norethisterone enanthate in obese and normalweight women found no difference in serum drug concentra tions between the two groups [24] . We found no studies evaluating the efficacy of norethis terone enanthate in women in different weight categories.
Progestin-only pills
Progestinonly pills are seldom used by women in the USA [25] . There is a lack of data on differ ential contraceptive efficacy between obese and nonobese users of progestinonly pills.
Combined hormonal contraceptives Combined oral contraceptive pills
The most common reversible contraceptive method in many markets is the combined oral contraceptive pill (COC) [103] . Since it became widely available in the 1960s, the dose of its com ponent hormones has steadily decreased. Most available COCs contain EE as the estrogenic component. There are a variety of progestins in current formulations, and the progestin compo nent is primarily responsible for the contraceptive effect. Progestins in sufficient doses suppress the hypothalamic-pituitary-ovarian axis leading to inhibition of ovulation. Secondary contraceptive effects include thickening of cervical mucus and thinning of the endometrial lining [26] . The estro gen component contributes to ovulation sup pression and control of irregular bleeding. The transdermal patch and vaginal ring also contain a combination of estrogen and progestin. Their mechanism of action is the same as COCs.
Few studies investigate the effects of obe sity on the PK of oral contraceptive steroids, although more studies are being carried out to address these concerns. We do know that COCs are subject to extensive firstpass metabolism by the liver [7] . A recent study compared the effects of a COC containing 20 µg EE and 100 µg LNG on the hypothalamic-pituitary-ovarian axis in obese versus nonobese women [27] . PK data for the two contraceptive steroids were also measured. Obese women were found to have significantly larger mean AUC (LNG and EE; p < 0.05), longer t½ (LNG; p < 0.05) and lower clearance (LNG and EE: p < 0.05) compared with normalweight women. Alterations in vol ume of distribution were less important con tributors, and the authors asserted that altera tions in clearance were the most significant, and most concerning, finding. Obese women also had higher levels of ovarian hormone produc tion (estradiol and progesterone) [27] , suggesting greater ovarian activity (and, therefore, poten tially decreased contraceptive efficacy) than normalweight women. The longer t½ identi fied in obese women corresponded to a longer time for the contraceptive hormones required to reach steady state following a 7day hormone free (placebo) interval. In one instance, steady state in one obese participant was not achieved even after the full 21day pill cycle [27] . This potentially creates a period of time -primar ily after pill initiation and possibly during pla cebo weeks -during which an obese woman using COCs is not adequately protected from pregnancy, or during which any gaps in com pliance may significantly increase her risk for c ontraceptive failure.
Another study compared the PK and phar macodynamics of a COC containing 30 µg EE and 150 µg LNG in normalweight and obese women [28] . Obese women were found to have lower AUC, C max and T max (the time to reach C max ) as well as an increased t½ of both EE and LNG, compared with normalweight women. The C min of both hormones were similar across the different BMI categories. Pharmacodynamic assessment consisted of twiceweekly trans vaginal ultrasounds to measure the presence of ovarian follicles. There was no significant differ ence in ovarian follicular activity by BMI. The authors concluded that despite the changes in PK parameters seen for LNG and EE, contraceptive efficacy was maintained in the obese participants since their LNG C min did not drop below the level needed to suppress ovulation.
PK studies are rarely powered to evaluate outcomes such as pregnancy. Larger studies that evaluate contraceptive failure rate are few and review -Robinson & Burke future science group Women's Health (2013) 9(5) CME results are mixed. An analysis of data from the 2002 National Survey of Family Growth found that women with a BMI greater than 30 kg/m 2 had a nonsignificant increased risk of method failure when using COCs for contraception, compared with normalweight women [29] . A case-control study investigating the pregnancy rate among COC users found a 60% increased risk of unintended pregnancy in all COC users with BMI >27.3 kg/m 2 (odds ratio [OR]: 1.58; 95% CI: 1.11-2.24), and 70% increased risk in users with BMI >32.3 kg/m 2 (OR: 1.72; 95% CI: 1.04-2.82). When only consistent COC users were analyzed, the odds of pregnancy were more than doubled for obese women. The authors state that this translates to an attributable risk of 2-4 additional pregnancies per 100 womenyears among overweight and obese COC users [30] . A Cochrane Review of 11 studies that used preg nancy as their primary outcome found that over weight or obese women (BMI >25 kg/m 2 ) were almost twice as likely to become pregnant while relying on COCs than their normalweight peers (OR: 1.91; 95% CI: 1.01-3.61) [31] . Data from 50,000 women in the USA, which were collected as part of a prospective, noninterventional cohort study, demonstrated higher oral contraceptive failure rates with higher BMI, when adjusted for age, parity and education level. Women with a BMI of 35 kg/m 2 or greater had a hazard ratio of 1.5 (95% CI: 1.3-1.8) for contraceptive fail ure, compared with women with a BMI less than 35 kg/m 2 [32] .
By contrast, a secondary analysis of the EURASOC study found no difference in overall contraceptive failure rates according to BMI or body weight [33] . When the analysis was stratified by individual progestins, only one -chlormadi none acetate -was found to be significantly asso ciated with contraceptive failure in obese women. Analysis from the Contraceptive CHOICE Proj ect found no increase in contraceptive failure rate by BMI category in users of COCs, patch or ring [34] . While the data conflict, the cumula tive conclusion seems to be that pregnancy rates among overweight and obese women using COC seem to be similar to or slightly higher than rates among normalweight women. The large num bers of women included in some studies, and the biological plausibility for altered PK, do suggest the possibility that COC may potentially be less efficacious in obese women.
It has been theorized that extended or con tinuous use of COC formulations may improve effectiveness compared with traditional monthly cycling in women of normal weight, by reducing or eliminating the hormonefree interval that has been identified as a time period of concern. This has not been conclusively demonstrated. A reanalysis of data from a Phase III clinical trial of the efficacy of a COC containing 20 µg EE and 100 µg LNG found no impact of body weight on pill efficacy. There was no significant difference in pregnancy rates across weight and BMI deciles [35] . However, this may currently be an understudied area of research.
Contraceptive patch
The contraceptive patch contains 6 mg norelge stromin and 0.75 mg EE, and each patch is worn for 7 days [36] . Compared with a daily COC containing the same hormones, the AUC of EE and norelgestromin delivered by the patch are higher than when taken orally [37] . Increased body weight and body surface area were associ ated with decreases in the AUC of both EE and norelgestromin among patch users, but these were not thought to be clinically significant.
A large randomized trial comparing efficacy of the patch to that of combined oral contra ceptives reported two pregnancies in patch users who weighed more than 80 kg [38] . However, women needed to be within 35% of ideal body weight in order to be enrolled, and the actual number of obese or overweight women was not reported. Subsequently, a pooled analysis of data for the con traceptive patch determined that women weigh ing more than 90 kg had a significantly increased failure rate compared with women weighing less than 90 kg [39] . Of 15 pregnancies that occurred during 22,160 treatment cycles, five of them occurred in women weighing more than 90 kg (who accounted for less than 3% of the study population). The authors concluded that women in this weight category may be at increased risk of contraceptive failure with use of the patch.
Contraceptive vaginal ring
The contraceptive vaginal ring provides a non oral, nondaily contraceptive method for women interested in shortterm birth control. The ring contains a total of 11.7 mg ENG and 2.7 mg EE, and releases these hormones at an average daily rate of 120 µg ENG and 15 µg EE [40] . The ring produces a lower serum peak EE concentration and lower EE AUC (indicating lower total sys temic exposure) than either COCs or the patch [38] . In normalweight women, the peak concen tration and AUC of ENG are similar between the ring and COCs.
Efficacy studies of the vaginal ring included very few obese women [41] . A recent study comparing serum and physiologic markers of ovulation in 18 normalweight and 19 obese women using the ring found lower EE concentrations in the obese participants, but no difference in ENG concen trations [42] . While this study was too small to assess pregnancy rates, there was no difference in ovarian follicle development or serum proges terone levels between the two groups, suggesting that c ontraceptive efficacy is maintained in obese women.
Even if combined methods are slightly less efficacious in obese women than in normal weight women, this is not equivalent to lack of efficacy. The possibility of lower efficacy of some shorteracting methods should lead to serious consideration of longeracting methods. How ever, any method of contraception is more effi cacious than no method. If a woman makes an informed choice to use a combined method, she should not be refused contraception based on body weight alone.
Postcoital (emergency) contraception
There are currently two FDAapproved emer gency contraceptive pills (ECPs) available in the USA. A levonorgestrelbased regimen involves either a single dose of 1.5 mg LNG or two doses of 0.75 mg LNG taken 12 h apart [43] . In the USA, LNG ECP has been available over the counter for women over the age of 17 years, and this was recently expanded to younger women as well. These dosing regimens are effective at reducing the risk of pregnancy up to 72 h after unprotected intercourse. Ulipristal acetate (UPA), a progesterone agonist/antagonist, is a onetime 30 mg dose that is effective up to 5 days after unprotected intercourse [44] . ECPs prevent pregnancy by inhibiting or delaying ovulation, and are most effective when taken soon after unprotected intercourse. When taken within 72 h of unprotected sex, the LNG ECP prevents approximately 50% of pregnancies while UPA prevents up to twothirds of pregnancies [45] .
Only two studies have investigated the effects of obesity on the efficacy of ECPs. Glasier et al. performed a metaanalysis of two randomized controlled trials comparing LNG with UPA for emergency contraception [46] . Among several covariates tested, BMI was found to have the greatest impact on risk of pregnancy after using either ECP method, but the risk was greater with LNG than UPA. The risk of pregnancy was fourtimes greater in obese women who took LNG ECPs compared with normalweight women (OR: 4.41; p < 0.05). Moreau and Trus sell performed a pooled analysis of UPA effi cacy, and found that obese women were twice as likely to experience ECP failure compared with nonobese women (OR: 2.1; 95% CI: 1.0-4.3; p = 0.04) [47] .
Safety concerns
An overestimation of contraceptive risk in obese women may lead to inadequate provision of effective contraceptive methods. In general, obese women may not receive preventive repro ductive health screenings as often as normal weight women [48] . For all women, including obese women, the risks of pregnancy generally outweigh the risk of potential harm from con traceptives. Hormonal contraception is a safe choice for obese women, in the absence of other contraindicating health conditions. The USA Medical Eligibility Criteria for Contraceptive Use and the WHO Medical Eligibility Crite ria for Contraceptive Use are evidencebased resources to guide provision of contraceptives for women with a wide range of medical conditions [49, 50] . Both documents advise that there are no safety concerns with the use of any progestin only contraceptive methods in obese women. This includes pills, injectables, implants and intrauterine contraception.
Furthermore, combined hormonal contracep tives (CHC) are also considered safe for use. The most concerning potential side effect of CHC is a venous or arterial thrombotic event.
Obese women are approximately twice as likely as normalweight women to experience venous thromboembolism (VTE), and obese women 
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who use COCs are more likely than obese women who do not use COCs to experience VTE [51, 52] . However, the absolute risk for VTE in women of reproductive age is small, and there is unlikely to be a significantly higher risk from one type of CHC compared with another [53, 54] . Furthermore, risks of VTE in pregnancy and postpartum are substantially higher than risks of VTE during contraceptive use. Thus, CHC are considered appropriate for obese women in the absence of other medical contraindications [45, 50] . A summary of recommendations from the CDC and WHO MEC regarding contracep tive use by obese women is presented in Table 3 .
It should be acknowledged that data to guide contraceptive provision for women with BMI >40 kg/m 2 were limited.
Bariatric surgery
No discussion of contraceptives and obesity would now be complete without consideration of bariatric weightloss surgery. This has been recognized as one of the most effective -and one of the few proven effective -treatments for obesity. The majority of reproductiveage patients undergoing bariatric surgery are women [55] , who are strongly advised to avoid pregnancy for up to 2 years after surgery [56] . The dramatic weightloss that follows bariatric surgery leads to improve ment in hypertension, diabetes and dyslipidemia, and can also lead to resumption of ovulation and normalization of menstrual irregularities [57] .
There are very limited data on the use of con traceptives after bariatric surgery, but there are theoretical concerns that both malabsorptive and restrictive procedures could decrease the absorp tion of oral contraceptives [52, 58] . The efficacy of nonoral methods is not believed to be affected by bariatric weightloss surgery, except that any obesityrelated effects that do exist will resolve as excess weight is lost [55] . Concerns for use of oral contraceptives after bariatric surgery are largely related to the type of surgery. There are three main categories of bar iatric surgery: restrictive, malabsorptive and com bined restrictive-malabsorptive. Purely malab sorptive procedures have fallen out of favor and are rarely performed. Restrictive procedures, which limit the size of the stomach and thus limit the amount of oral intake, include the popular gastric banding operations. Since restrictive procedures do not interfere with the absorptive capacity of the gut, they are not believed to decrease efficacy of oral contraceptives. Restrictive-malabsorptive procedures, however, may be a different story. A common example of such a procedure is the RouxenY gastric bypass. This procedure both surgically limits the size of the stomach (restric tive component) and bypasses a significant por tion of the duodenum, intentionally creating a malabsorptive state. This mal absorption may also decrease the ability of the gut to absorb hormones from oral contraceptives, which could in turn decrease their contraceptive efficacy. This con cern is based on limited data from poorly designed studies [52] . However, the concern is sufficient that the US MEC, which otherwise focuses primarily on contraceptive safety, advises against the use of oral contraceptives in women after gastric bypass surgery [45] . For women who have undergone gas tric bypass surgery, there is also concern that sub sequent malabsorption could reduce the efficacy of ECPs [45] . Table 4 summarizes recommendations for contraceptive use in women who have had bar iatric weightloss surgery. Current research in this area is ongoing. 
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Discussion
To date, providers of hormonal contraceptive methods employ a onesizefitsall approach. Most PK studies exclude women who are greater than 130% of their ideal body weight and these studies typically note significant interindividual variability in serum concentrations of contracep tive hormones, even among normalweight par ticipants. Similarly, clinical trials of new contra ceptives have historically excluded obese women. However, all women are given the same dosages of contraceptive hormones regardless of weight. The significant variability in serum hormone concentrations among individuals begs the ques tion of whether this onesizefitsall approach is realistic, especially given the rising preva lence of obesity and the serious consequences of inadequate contraception. The question is also relevant given that the dose of EE in oral con traceptives has steadily decreased over the last several decades. It is unclear whether these lower doses are exposing women to increased risk of contraceptive failure [59] . Evidence to date is reassuring that many contra ceptive methods maintain their efficacy in obese women. Despite conflicting information regard ing the efficacy of some hormonal contraceptives in obese women, it is important to remember that any contraceptive, even if less efficacious, is a better and safer choice than no method at all. Overweight and obese women are at increased risk of pregnancy complications, including gestational diabetes, hypertensive complications and cesarean delivery [60] . Since it is unclear how much obesity may reduce the efficacy of shortacting contra ceptives in particular, it seems overly alarmist to restrict the use of these methods in overweight and obese women. Highly effective, longacting, reversible contraceptive methods provide the most reliable contraception for all women, regardless of weight. These should be considered firstline methods for obese and overweight women and can be offered to all appropriate candidates.
Conclusion
Obesity affects a continuously growing num ber of reproductiveaged women, and helping obese women manage their reproductive health is as important as with any chronic disease. Healthcare providers who understand how obesity may affect the efficacy of hormonal contraceptives will be better able to assist their patients in reproductive decisionmaking. As more obese women chose to undergo bariatric surgery, it will be important to investigate what effects, if any, such surgeries have on contracep tive efficacy. Providing effective contraception is also a crucial part of helping obese women undergo weight loss therapy. Increasing use of longacting reversible contraception methods has the potential to avoid the PK and pharma codynamics changes that accompany obesity while maximizing use of the most effective c ontraceptive methods
Future perspective
Obese women represent a population whose reproductive health is greatly affected by their weight, yet factors that influence contraceptive efficacy in this population are poorly under stood. Research is beginning to focus on the best contraceptive methods for overweight and obese women. Elucidating the relationship between obesity and contraceptive efficacy should con tinue to be a focus of future research, and eval uation of new contraceptive methods should p roactively include obese women.
Future directions should also include the integration of contraceptive provision into weightloss programs. This will enable women to improve their health before undertaking the demands of pregnancy, and will also reduce their risk of obesityrelated complications of pregnancy. Encouraging obese women to con sider the most effective, reversible contraceptive methods maximizes their contraceptive and noncontraceptive benefits.
Executive summary
Pharmacokinetic implications: cause for concern?
• Obesity is a prevalent health problem and may affect the pharmacokinetics and efficacy of hormonal contraceptives.
Efficacy of hormonal contraceptives among obese women
• Limited data suggest that long-acting reversible contraceptives methods (intrauterine devices and implants) retain excellent contraceptive efficacy in obese women. • Oral contraceptives, the contraceptive patch and emergency contraceptive pills have been shown to have increased failure rates in obese women compared with normal-weight women. The risk of failure appears to be greatest in those women with the highest BMI (>35 kg/m 2 ). • The use of any hormonal contraceptive is more effective at preventing pregnancy than using no method. Obese women should be offered a full range of contraceptive options with a candid discussion of each method's risks, benefits and alternatives. 
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